2fluoro2deoxy

2-fluoro-2-deoxy-D-glucose, often abbreviated as 2-FDG or [18F]FDG, is a glucose analog used in medical imaging. It is a radioactive tracer that mimics glucose, the primary energy source for most cells. When administered to a patient, 2-FDG is taken up by cells and phosphorylated by hexokinase to form 2-FDG-6-phosphate. However, unlike glucose-6-phosphate, 2-FDG-6-phosphate cannot be further metabolized by glycolysis or glycogen synthesis, causing it to become trapped within cells. The rate of 2-FDG uptake and trapping is proportional to the metabolic activity of the cells.

This property makes 2-FDG invaluable for Positron Emission Tomography (PET) imaging. In a PET scan, the emitted positrons from the radioactive fluorine-18 isotope interact with electrons in the surrounding tissue, producing gamma rays. These gamma rays are detected by the PET scanner, allowing for the creation of detailed images that show areas of high and low metabolic activity. Cancer cells, which typically have a higher rate of glucose metabolism than surrounding normal tissues, often exhibit increased uptake of 2-FDG. This allows PET scans with 2-FDG to detect the presence of tumors, assess their spread (metastasis), and monitor the effectiveness of cancer treatment.

Beyond oncology, 2-FDG PET imaging is also used in the diagnosis and management of neurological disorders, such as Alzheimer's disease and epilepsy, and to assess cardiac viability. The distribution and uptake patterns of 2-FDG in the brain can reveal patterns of neuronal activity and glucose metabolism. The development and widespread use of 2-FDG have revolutionized molecular imaging, providing unprecedented insights into the physiological and pathological processes within the human body.